Results show drug is effective and safe, leaves open question of optimal dosing
News | Cardiovascular Clinical Studies
Study Finds Olezarsen Cuts Triglyceride Levels by About Half

April 7, 2024 — An estimated 1 in 5 U.S. adults—and more than 2 in 5 adults aged 60 years and older—have elevated ...

Home April 07, 2024
Home
90% of high-risk patients on lerodalcibep achieved guideline-recommended cholesterol targets
News | Cardiovascular Clinical Studies
Novel PCSK9 Inhibitor Cut LDL Cholesterol Levels by More Than Half

April 7, 2024 — Among patients at high or very high risk for a heart attack or stroke, the addition of the ...

Home April 07, 2024
Home
Novel drug shows promise for treating severe hypertriglyceridemia in patients at high risk for pancreatitis
News | Cardiovascular Clinical Studies
Plozasiran Reduces Triglyceride Levels by 74% at 24 Weeks

April 7, 2024 — In patients with severely elevated triglyceride levels at risk for developing acute pancreatitis, the ...

Home April 07, 2024
Home
Study shows no benefit for heart failure overall but suggests different effects in those with preserved versus reduced ejection fraction
News | Cardiovascular Clinical Studies
RELIEVE-HF Trial Outcomes Reported at ACC.24 Find Impact of Interatrial Shunt May Vary by Heart Failure Type

April 6, 2024 — Patients with heart failure who had a small shunt inserted between the heart’s left and right atria did ...

Home April 06, 2024
Home
While composite of death and heart failure hospitalizations was not significantly reduced, empagliflozin may help reduce heart failure risks after a heart attack
News | Cardiovascular Clinical Studies
EMPACT-MI Trial Outcomes Reported at ACC.24: SGLT-2 Inhibitors Show Mixed Results After Heart Attack

April 6, 2024 — Use of the sodium glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin following a heart attack did ...

Home April 06, 2024
Home
Exploratory analysis finds beneficial effect on patient outcomes at one year, according to a study presented at ACC.24.
News | Cardiovascular Clinical Studies
Research Presented at ACC 2024 Found No Reduction in 90-Day Deaths, Heart Attacks With Human Apo/A1

April 6, 2024 — The first trial of a novel strategy for removing cholesterol from patients’ arteries did not reduce the ...

Home April 06, 2024
Home
The Minneapolis Heart Institute Foundation (MHIF) is presenting data on trends in ST-elevation myocardial infarction (STEMI) at the American College of Cardiology’s Annual Scientific Session (ACC.24). An analysis of nearly 8,000 STEMI patients over 20 years found the majority of STEMI occur in individuals without prior cardiovascular disease.
News | ACC
Research Data from Minneapolis Heart Institute Foundation at ACC 2024 Reveal Trends in Cardiovascular Risk Factors and Preventive Medication Use Prior to Heart Attacks

April 6, 2024 — The Minneapolis Heart Institute Foundation (MHIF) is presenting leading research focused on trends in ST ...

Home April 06, 2024
Home
Smidt Heart Institute experts will be available for media interviews throughout ACC.24.
News | Artificial Intelligence
ACC.24: Smidt Heart Institute Experts to Share Research Findings, Clinical Knowledge

April 6, 2024 — Experts from the Smidt Heart Institute at Cedars-Sinai will share new research and participate in more ...

Home April 06, 2024
Home
Registration is open for a leading conference on structural heart disease announced by the Cardiovascular Research Foundation, CRF.
News | Cardiovascular Business
Cardiovascular Research Foundation, CRF, Introduces New York Valves: The Structural Heart Summit

April 5, 2024 — The Cardiovascular Research Foundation (CRF) has announced New York Valves: The Structural Heart Summit ...

Home April 05, 2024
Home
Cardiawave SA will present the 30-day follow-up results for 60 patients enrolled in its European pivotal study to the 73rd annual conference of the American College of Cardiology in Atlanta, Georgia
News | Cardiovascular Ultrasound
Cardiawave is Presenting the 30-day Follow-up Results from its “Valvosoft Pivotal Study” on the Teatment of Severe Symptomatic Aortic Valve Stenosis at ACC24

April 5, 2024 — Cardiawave SA, a French medtech company that has developed an innovative Non-Invasive focused Ultrasound ...

Home April 05, 2024
Home
The acquisition enhances Johnson and Johnson’s ability to transform the treatment landscape for cardiovascular disease and continue to improve patient outcomes
News | Cardiovascular Business
Johnson and Johnson to Acquire Shockwave Medical

April 5, 2024 — Johnson & Johnson and Shockwave Medical, Inc. today announced that they have entered into a definitive ...

Home April 05, 2024
Home
Viz.ai will be announced new clinical data supporting advancements in cardiology care during the American College of Cardiology Scientific Sessions, ACC.24
News | Artificial Intelligence
Real-world Evidence at the American College of Cardiology Scientific Session ACC.24 to Demonstrate Positive Impact of Viz.ai on Suspected Disease Detection and Patient Triage for Improved Care

April 4, 2024 — Viz.ai, a leader in AI-powered disease detection and intelligent care coordination, announced new ...

Home April 04, 2024
Home
Virtual Reality Simulation Company Collaborates with American College of Cardiology to Help Cardiovascular Clinicians Immersively Practice Clinical Procedures
News | Left Atrial Appendage (LAA) Occluders
Osso VR Expands Cardiology Training through ACC Collaboration

April 4, 2024 — Osso VR, a leader in immersive procedural training, announces the release of a co-developed curriculum ...

Home April 04, 2024
Home
Early coronary disease and impaired heart function, with increased coronary vessel wall thickness, in asymptomatic, middle-aged individuals living with HIV has been reported in a new study published today in Radiology: Cardiothoracic Imaging, a journal of the Radiological Society of North America (RSNA).
News | Population Health
New Study Finds Early Coronary Disease, Impaired Heart Function in Asymptomatic People with HIV

April 4, 2024 — A new study found increased coronary vessel wall thickness that was significantly associated with ...

Home April 04, 2024
Home
The FDA has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries or death. 
News | Balloon Catheter
FDA Announces Medos International Sàrl Recall of Cerenovus CEREBASE DA Guide Sheath due to Cracking of the Distal Catheter Shaft

April 4, 2024 — The U.S. Food and Drug Administration (FDA) announced that Medos International Sàrl is recalling ...

Home April 04, 2024
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now